CAS
AXSM icon

Coppell Advisory Solutions’s Axsome Therapeutics AXSM Stock Holding History

Coppell Advisory Solutions’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,747
Closed -$1.9M – 47
2025
Q4 		$1.9M Buy
+12,747
New +$1.78M 0.19% 113

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Coppell Advisory Solutions's AXSM Position: Q1 2026 in Review

Coppell Advisory Solutions sold out of Axsome Therapeutics (AXSM) in Q1 2026, closing a stake of 12,747 shares — an estimated $1.9M sold.

Coppell Advisory Solutions first reported a position in AXSM in Q4 2025 and held it in 1 quarter. The position peaked at $1.9M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Coppell Advisory Solutions reported no remaining Axsome Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Coppell Advisory Solutions sold 12,747 Axsome Therapeutics shares in Q1 2026, an estimated $1.9M.
  • Coppell Advisory Solutions first reported a position in Axsome Therapeutics in Q4 2025 and held it in 1 quarter.
  • Coppell Advisory Solutions's Axsome Therapeutics position peaked at $1.9M in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Coppell Advisory Solutions's 13F filing for Q1 2026, filed 15 May 2026.